Orange County NC Website
Browse       Search
3 <br /> Supplemental Agreement for Additional Funds <br /> From Additional Settlements of Opioid Litigation <br /> I. PURPOSE <br /> The purpose of this Supplemental Agreement for Additional Funds ("SAAF") is to <br /> direct Additional Funds from Additional Settlements of opioid litigation to the state <br /> of North Carolina and local governments in a manner consistent with the <br /> Memorandum of Agreement ("MOA") Between the State of North Carolina and <br /> Local Governments on Proceeds Relating to the Settlement of Opioid Litigation that <br /> has governed the distribution of Opioid Settlement Funds to the State and its Local <br /> Governments since May 2022. <br /> This SAAF does not change the scope or meaning of the MOA with respect to Opioid <br /> Settlement Funds governed by the MOA. Instead, this SAAF applies the terms of <br /> the MOA— with certain clarifications noted below —to the Additional Settlements <br /> and Additional Funds described below. <br /> II. SCOPE <br /> A. Scope of the MOA. Under the terms of the MOA, the MOA governs Opioid <br /> Settlement Funds from: <br /> 1. The National Settlement Agreement with the drug distributors <br /> Cardinal, McKesson, and AmerisourceBergen and the drug maker <br /> Johnson & Johnson and its subsidiary Janssen Pharmaceuticals; and <br /> 2. The Bankruptcy Resolution with Mallinckrodt; any Bankruptcy <br /> Resolution with Purdue; and any other Bankruptcy Resolution as the <br /> term "Bankruptcy Resolution" is defined in the MOA. <br /> B. Scope of this SAAF. This SAAF governs Additional Funds from the <br /> Additional Settlements with Additional Settling Defendants Walmart, Inc., <br /> Teva Pharmaceutical Industries Ltd., Allergan Finance, LLC, Allergan <br /> Limited, CVS Health Corporation, CVS Pharmacy, Inc., and Walgreen Co., as <br /> well as their subsidiaries, affiliates, officers, and directors named in the <br /> Additional Settlements. <br /> 1 <br />